LGND | Ligand Pharmaceuticals Incorporated Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	112.53 - 117.53
52 Week Range	67.72 - 129.90
Beta	1.09
Implied Volatility	51.24%
IV Rank	47.66%
Day's Volume	106,108
Average Volume	126,245
Shares Outstanding	18,895,400
Market Cap	2,217,564,144
Sector	Healthcare
Industry	Biotechnology
IPO Date	1992-11-18

Valuation
Profitability
Growth
Health
P/E Ratio	46.94
Forward P/E Ratio	78.17
EPS	2.50
1YR Price Target	180.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	58
Country	USA
Website	LGND

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

LGND's peers: PASG, ORIC, LYEL, DSGN, ASND, APLS, BGNE, AKRO, BPMC, VRDN, TERN, GPCR, ETNB, CRNX, CYTK, ICVX, RCUS, CGEM, ANNX, RLAY, OMER

*Chart delayed

Analyzing fundamentals for LGND we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is poor, Growth is exceptionally good and Health is very strong. For more detailed analysis please see LGND Fundamentals page.

Watching at LGND technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LGND Technicals page.